Get the Stockscreener App
0.171
6.28%
0.0101
After Hours:
.17
-0.001
-0.58%
Vivosim Labs Inc stock is traded at $0.171, with a volume of 3.35M.
It is up +6.28% in the last 24 hours and down -37.25% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$0.1609
Open:
$0.157
24h Volume:
3.35M
Relative Volume:
3.85
Market Cap:
$2.29M
Revenue:
$142.00K
Net Income/Loss:
$-1.23M
P/E Ratio:
0.3672
EPS:
0.4657
Net Cash Flow:
$-10.62M
1W Performance:
-3.50%
1M Performance:
-37.25%
6M Performance:
-88.68%
1Y Performance:
-94.04%
1-Day Range:
$0.1495
$0.19
1-Week Range:
$0.1495
$0.19
52-Week Range:
$0.1495
$3.40
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.171 | 2.29M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
Press Releases about Volato Group, Inc. Class A Common Stock (NYSE:SOAR) - FinancialContent
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials - Carroll County Mirror-Democrat
Received 5M from Eli Lilly - Moomoo
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - openPR.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - WBOC TV
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - marketscreener.com
VivoSim Labs (VIVS) CCO buys 10,000 shares outside trading plan - Stock Titan
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - FinancialContent
VivoSim plans rat liver model to complement human testing - Investing.com
VivoSim Labs to Add Rat Liver Model to NAMkind Platform - Yahoo Finance UK
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - Barchart.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
Big Pharma giant Eli Lilly pays $6M to VivoSim Labs 🤯🔥 $Xiao-I (AIXI.US)$ $CID Holdco (DAIC.US)$ - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - openPR.com
VivoSim Labs (VIVS) News Flow - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
The Largest Pharma On The Planet Sent Cash to a Micro cap 👀 - Moomoo
VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VivoSim Labs, INC. SEC Filing (Aug 21, 2026) - Stock Titan
Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10% - Stock Titan
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - WBOC TV
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - FinancialContent
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as - openPR.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus - FinancialContent
VivoSim Labs (VIVS) seeks approval for reverse split, equity plan and warrant repricing - Stock Titan
VivoSim: Fiscal Q1 Earnings Snapshot - marketscreener.com
VivoSim: Fiscal Q1 Earnings Snapshot - KTVB
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside - FinancialContent
$VIVS Load up 🔥🚀 - Moomoo
VivoSim Labs, INC. SEC Filing (Aug 11, 2026) - Stock Titan
VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance - Stock Titan
VivoSim Labs (VIVS) Revenue BreakdownMain Composition - Moomoo
VivoSim Labs (VIVS) News Flow - Moomoo
VIVS PE Ratio & Valuation, Is VIVS Overvalued - Intellectia AI
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Moomoo
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com UK
VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 - Minichart
VivoSim Labs regains Nasdaq compliance after cash infusion - Investing.com
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com Nigeria
🍋💦🍋💦💣🚀 - Moomoo
VivoSim Provides Financial and Listing Compliance Update - The Manila Times
VivoSim regains Nasdaq compliance after $10.1 million cash update - Quiver Quantitative
Vivosim Labs Inc Stock (VIVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):